Browsing by Author "Im, Wonpil"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    CHARMM at 45: Enhancements in Accessibility, Functionality, and Speed
    (American Chemical Society, 2024) Hwang, Wonmuk; Austin, Steven L.; Blondel, Arnaud; Boittier, Eric D.; Boresch, Stefan; Buck, Matthias; Buckner, Joshua; Caflisch, Amedeo; Chang, Hao-Ting; Cheng, Xi; Choi, Yeol Kyo; Chu, Jhih-Wei; Crowley, Michael F.; Cui, Qiang; Damjanovic, Ana; Deng, Yuqing; Devereux, Mike; Ding, Xinqiang; Feig, Michael F.; Gao, Jiali; Glowacki, David R.; Gonzales, James E., II; Hamaneh, Mehdi Bagerhi; Harder, Edward D.; Hayes, Ryan L.; Huang, Jing; Huang, Yandong; Hudson, Phillip S.; Im, Wonpil; Islam, Shahidul M.; Jiang, Wei; Jones, Michael R.; Käser, Silvan; Kearns, Fiona L.; Kern, Nathan R.; Klauda, Jeffery B.; Lazaridis, Themis; Lee, Jinhyuk; Lemkul, Justin A.; Liu, Xiaorong; Luo, Yun; MacKerell, Alexander D., Jr.; Major, Dan T.; Meuwly, Markus; Nam, Kwangho; Nilsson, Lennart; Ovchinnikov, Victor; Paci, Emanuele; Park, Soohyung; Pastor, Richard W.; Pittman, Amanda R.; Post, Carol Beth; Prasad, Samarjeet; Pu, Jingzhi; Qi, Yifei; Rathinavelan, Thenmalarchelvi; Roe, Daniel R.; Roux, Benoit; Rowley, Christopher N.; Shen, Jana; Simmonett, Andrew C.; Sodt, Alexander J.; Töpfer, Kai; Upadhyay, Meenu; van der Vaart, Arjan; Vazquez-Salazar, Luis Itza; Venable, Richard M.; Warrensford, Luke C.; Woodcock, H. Lee; Wu, Yujin; Brooks, Charles L., III; Brooks, Bernard R.; Karplus, Martin; Chemistry and Chemical Biology, School of Science
    Since its inception nearly a half century ago, CHARMM has been playing a central role in computational biochemistry and biophysics. Commensurate with the developments in experimental research and advances in computer hardware, the range of methods and applicability of CHARMM have also grown. This review summarizes major developments that occurred after 2009 when the last review of CHARMM was published. They include the following: new faster simulation engines, accessible user interfaces for convenient workflows, and a vast array of simulation and analysis methods that encompass quantum mechanical, atomistic, and coarse-grained levels, as well as extensive coverage of force fields. In addition to providing the current snapshot of the CHARMM development, this review may serve as a starting point for exploring relevant theories and computational methods for tackling contemporary and emerging problems in biomolecular systems. CHARMM is freely available for academic and nonprofit research at https://academiccharmm.org/program.
  • Thumbnail Image
    Item
    Potential pharmacological chaperones targeting cancer-associated MCL-1 and Parkinson disease-associated α-synuclein
    (PNAS, 2014-07-29) Oh, Misook; Le, Ji Hoon; Wang, Wei; Sun Lee, Hui; Sirl Lee, Woo; Burlak, Christopher; Im, Wonpil; Hoang, Quyen; Lim, Hyun-Suk; Department of Biochemistry & Molecular Biology, IU School of Medicine
    Pharmacological chaperones are small molecules that bind to proteins and stabilize them against thermal denaturation or proteolytic degradation, as well as assist or prevent certain protein-protein assemblies. These activities are being exploited for the development of treatments for diseases caused by protein instability and/or aberrant protein-protein interactions, such as those found in certain forms of cancers and neurodegenerative diseases. However, designing or discovering pharmacological chaperones for specific targets is challenging because of the relatively featureless protein target surfaces, the lack of suitable chemical libraries, and the shortage of efficient high-throughput screening methods. In this study, we attempted to address all these challenges by synthesizing a diverse library of small molecules that mimic protein α-helical secondary structures commonly found in protein-protein interaction surfaces. This was accompanied by establishing a facile "on-bead" high-throughput screening method that allows for rapid and efficient discovery of potential pharmacological chaperones and for identifying novel chaperones/inhibitors against a cancer-associated protein, myeloid cell leukemia 1 (MCL-1), and a Parkinson disease-associated protein, α-synuclein. Our data suggest that the compounds and methods described here will be useful tools for the development of pharmaceuticals for complex-disease targets that are traditionally deemed "undruggable."